Patent ID: 8389500

Claim:
A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of reducing late sodium current, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula (IA) or (IB): wherein: R 1 is hydrogen, C 1-4 alkyl, —R 25 —O—R 20 , —R 25 —C(O)—O—R 20 , —R 25 —C(O)NHS(O) 2 R 20 , —R 25 -optionally substituted monocyclic heterocyclyl, —R 25 -optionally substituted monocyclic cycloalkyl, —R 25 -optionally substituted monocyclic heteroaryl, —R 25 -optionally substituted monocyclic aryl; wherein the heterocyclyl, cycloalkyl, aryl, and heteroaryl are optionally substituted with one, two, or three substituents independently selected from halo, hydroxyl, alkyl, —R 25 —C(O)—O—R 20 , —R 25 —S(O) 2 —R 20 , lower alkoxy, —CF 3 , —CN, amino, —NO 2 , mono- or dialkylamino, and heteroaryl; R 2 and R 5 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, halo, CN, —CF 3 , —O—R 20 , —S—R 20 , —C(O)—O—R 20) —C(O)—N(R 20 )(R 22 ), and —P(O)(OR 20 ) 2 ; R 3 and R 4 are hydrogen; R 7 is C 1-4 alkyl or cycloalkyl; R a are each independently selected from the group consisting of C 1-4 alkyl, halo, CN,—NO 2 , —CF 3 , —O—R 20 , —S—R 20 , —C(O)—O—R 20 ,—C(O)—N(R 20 )(R 22 ), —N(R 20 )(R 22 )—N(R 20 )—C(O)—R 22 ,—P(O)(OR 20 ) 2 , —R 25 -optionally substituted monocyclic heteroaryl, and —R 25 -optionally substituted monocyclic aryl; provided that the optionally substituted monocyclic heteroaryl is not a 6-membered monocyclic heteroaryl group; wherein the aryl and heteroaryl are optionally substituted with one, two, or three substituents independently selected from halo, hydroxyl, alkyl, monoalkylamino, dialkylamino, alkyl, aryl or heteroaryl amide, —CN, lower alkoxy, —CF 3 , aryl, and heteroaryl; n is 0, 1, 2, or 3; R 20 and R 22 are in each instance independently selected from the group consisting of hydrogen, C 1 -C 15 alkyl, C 2 -C 15 alkenyl, C 2 -C 15 alkynyl, heterocyclyl, aryl, and heteroaryl; wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one, two, or three substituents independently selected from halo, hydroxyl, alkyl, mono- or dialkylamino, alkyl, aryl or heteroaryl amide, —CN, lower alkoxy, —CF 3 , aryl, and heteroaryl; R 25 is in each instance independently a covalent bond or selected from C 1 -C 3 alkylene optionally substituted with one or two C 1 -C 3 alkyl groups; or a pharmaceutically acceptable salt or ester thereof.